BMJ  2007;334:178 (27 January), doi:10.1136/bmj.39101.376100.80

News

Shortcuts from other journals

Expected survival exceeds 35 years for young Danes with HIV

The first 150 words of the full text of this article appear below.


Figure Removed (Available Only in the Full Text)
View larger version (69K):



 
 
Death rates in people with HIV have fallen substantially since 1995 thanks to highly active antiretroviral therapy (HAART). The latest figures from Denmark suggest that a 25 year old with the infection can now expect to survive for more than 35 years (median 38.9). Concurrent infection with hepatitis C reduced survival to around 32 yearsGo.

These estimates are probably the most robust so far because they are derived from a cohort comprising all Danish adults with HIV. But the estimates depend on HAART continuing to work well for life. The authors who compiled these figures say they found no evidence that HAART becomes less effective over time, despite potential problems with multidrug resistance and serious side effects.

Prognosis for people with HIV now approaches that associated with type 1 diabetes, but only in countries like Denmark where all citizens have free access to modern drug treatments and careful follow-up. . . . [Full text of this article]


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to StumbleUpon StumbleUpon   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Access jobs at BMJ Careers
Whats new online at Student BMJ